Inflammatory protein trajectories and severe respiratory failure in COVID-19: a secondary analysis of the SAVE-MORE randomised trial

BACKGROUND: Severe COVID-19 is characterised by maladaptive host inflammation. In the SAVE-MORE trial (EudraCT no. 2020-005828-11; ClinicalTrials.gov NCT04680949), suPAR-guided anakinra treatment reduced mortality and progression to severe respiratory failure (SRF), but the underlying molecular mechanisms remain unclear. METHODS: We performed longitudinal proteomic profiling (Olink Inflammation panel, 67 proteins) in 587 SAVE-MORE participants (400 treated with anakinra and 187 with placebo), of whom 453 had samples at all three time points (baseline, Day 4, and Day 7). Analyses aimed to (i) identify baseline predictors of SRF, (ii) define inflammatory trajectories using mixed-effects models, and (iii) characterise proteomic changes at SRF onset. Cox models identified prognostic markers, validated in an independent anakinra-treated cohort from the SAVE trial (n = 153). FINDINGS: Multivariate Cox regression models adjusted for sex, age, BMI, and dexamethasone treatment showed that baseline IL-6 concentrations predicted SRF across both treatment arms (placebo HR = 1·99, CI: 1·31-3·02; anakinra HR = 2·12, CI: 1·56-2·87), while PD-L1 predicted SRF only in the placebo group (HR = 2·75, CI: 1·79-4·24). Anakinra allocation was associated with changes in inflammatory trajectories related to SRF progression. Patients developing SRF showed sustained activation marked by elevated concentrations of IL-6, MCP-1/3, EN-RAGE, and PD-L1, whereas SRF-free patients had higher levels of proteins linked to regulatory and adaptive immunity, including CD6, CD244, TRAIL, TNF-B, and FLT3L. Event-aligned analyses showed an acute inflammatory surge at SRF onset involving IL-6, CXCL5, OSM, and VEGFA, which was significantly attenuated by anakinra. Results were further confirmed in the SAVE cohort. INTERPRETATION: Progression to SRF was associated with an inflammatory amplification programme involving cytokine, chemokine, tissue-injury, and immune-checkpoint pathways. Anakinra allocation was associated with smaller changes in proteins associated with inflammatory amplification and acute inflammatory changes accompanying respiratory deterioration. These findings provide biological context for the clinical benefit observed in the SAVE-MORE trial. FUNDING: Hellenic Institute for the Study of Sepsis (sponsor) and Swedish Orphan Biovitrum (funder).

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2026-11-18
DOI
https://doi.org/10.1016/j.ebiom.2026.106561
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inflammatory protein trajectories and severe respiratory failure in COVID-19: a secondary analysis of the SAVE-MORE randomised trial

Periklis Panagopoulos, Carlo Francesco Selmi, Agamemnon Bakakos, Emmanouil Stylianakis et al.
1 links
EBioMedicine
COVID-19 Clinical Research Studies
article

Inflammatory protein trajectories and severe respiratory failure in COVID-19: a secondary analysis of the SAVE-MORE randomised trial

Periklis Panagopoulos, Carlo Francesco Selmi, Agamemnon Bakakos, Emmanouil Stylianakis, Nick Keur, Evangelos J. Giamarellos‐Bourboulis, Isis Ricaño-Ponce, Konstantina Iliopoulou, Lorenzo Dagna, Evangelos Siarkos, Glykeria Tzatzagou, Ilias Kainis, Sofia Ioannou, Matteo Bassetti, Styliani Sympardi, Francesco Saverio Serino, Emanuele Nicastri, Katerina Dimakou, Mihai G. Netea, Aggeliki Rapti, Archontoula Fragkou, Francesco Castelli, Maria Chini, Maria Dafni, Georgios Chrysos, Aikaterini Argyraki, Aikaterini Masgala, Andrea Angheben, George D. Tsoukalas, Karolina Akinosoglou, Georgios Adamis, Eleni Florou, Vassiliki Rapti, Pierluigi Del Vecchio, Ilias C. Papanikolaou, Konstantinos Syrigos, Haralampos J. Milionis, George N. Dalekos, Simeon Metallidis, Ioannis Kalomenidis, Vasileios Kotsis, Michael Samarkos, Michael Doumas, Vinod Kumar
article en

Abstract

BACKGROUND: Severe COVID-19 is characterised by maladaptive host inflammation. In the SAVE-MORE trial (EudraCT no. 2020-005828-11; ClinicalTrials.gov NCT04680949), suPAR-guided anakinra treatment reduced mortality and progression to severe respiratory failure (SRF), but the underlying molecular mechanisms remain unclear. METHODS: We performed longitudinal proteomic profiling (Olink Inflammation panel, 67 proteins) in 587 SAVE-MORE participants (400 treated with anakinra and 187 with placebo), of whom 453 had samples at all three time points (baseline, Day 4, and Day 7). Analyses aimed to (i) identify baseline predictors of SRF, (ii) define inflammatory trajectories using mixed-effects models, and (iii) characterise proteomic changes at SRF onset. Cox models identified prognostic markers, validated in an independent anakinra-treated cohort from the SAVE trial (n = 153). FINDINGS: Multivariate Cox regression models adjusted for sex, age, BMI, and dexamethasone treatment showed that baseline IL-6 concentrations predicted SRF across both treatment arms (placebo HR = 1·99, CI: 1·31-3·02; anakinra HR = 2·12, CI: 1·56-2·87), while PD-L1 predicted SRF only in the placebo group (HR = 2·75, CI: 1·79-4·24). Anakinra allocation was associated with changes in inflammatory trajectories related to SRF progression. Patients developing SRF showed sustained activation marked by elevated concentrations of IL-6, MCP-1/3, EN-RAGE, and PD-L1, whereas SRF-free patients had higher levels of proteins linked to regulatory and adaptive immunity, including CD6, CD244, TRAIL, TNF-B, and FLT3L. Event-aligned analyses showed an acute inflammatory surge at SRF onset involving IL-6, CXCL5, OSM, and VEGFA, which was significantly attenuated by anakinra. Results were further confirmed in the SAVE cohort. INTERPRETATION: Progression to SRF was associated with an inflammatory amplification programme involving cytokine, chemokine, tissue-injury, and immune-checkpoint pathways. Anakinra allocation was associated with smaller changes in proteins associated with inflammatory amplification and acute inflammatory changes accompanying respiratory deterioration. These findings provide biological context for the clinical benefit observed in the SAVE-MORE trial. FUNDING: Hellenic Institute for the Study of Sepsis (sponsor) and Swedish Orphan Biovitrum (funder).

EBioMedicineVol. 134
Nitte University (IN), University of Bonn (DE), Radboud University Nijmegen (NL), Democritus University of Thrace (GR), Vita-Salute San Raffaele University (IT), University of Patras (GR), University of Ioannina (GR), National and Kapodistrian University of Athens (GR), Aristotle University of Thessaloniki (GR), Agostino Gemelli University Polyclinic (IT), Radboud University Medical Center (NL), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Ospedale Sacro Cuore Don Calabria (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Papageorgiou General Hospital (GR), General Hospital of Athens G. Genimatas (GR), University Hospital of Larissa (GR), Corfu General Clinic (GR), General Hospital of Athens Elpis (GR), General Hospital Asklepieio Voulas (GR), Tzaneion General Hospital (GR), IRCCS Ospedale San Raffaele (IT), Ospedale Policlinico San Martino (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), IRCCS Humanitas Research Hospital (IT), Life & Brain (Germany) (DE), Evangelismos Hospital (GR), Sotiria General Hospital (GR), General Hospital of Larisa, Greece (GR), Hellenic Institute for the Study of Sepsis (GR), University of Brescia (IT), University of Genoa (IT)
ZonMw, Swedish Orphan Biovitrum, Hellenic Institute for the Study of Sepsis
Good health and well-being
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon